Cargando…

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://www.ncbi.nlm.nih.gov/pubmed/27166836
http://dx.doi.org/10.1111/cas.12965
_version_ 1782443060792131584
author Matsuda, Yasufumi
Yamauchi, Takahiro
Hosono, Naoko
Uzui, Kanako
Negoro, Eiju
Morinaga, Koji
Nishi, Rie
Yoshida, Akira
Kimura, Shinya
Maekawa, Taira
Ueda, Takanori
author_facet Matsuda, Yasufumi
Yamauchi, Takahiro
Hosono, Naoko
Uzui, Kanako
Negoro, Eiju
Morinaga, Koji
Nishi, Rie
Yoshida, Akira
Kimura, Shinya
Maekawa, Taira
Ueda, Takanori
author_sort Matsuda, Yasufumi
collection PubMed
description The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resistant CML cells in vitro. Two different IM‐resistant cell lines, K562/IM‐R1 and Ba/F3/T315I were evaluated in comparison with their respective, parental cell lines, K562 and Ba/F3. K562/IM‐R1 overexpressed BCR‐ABL due to gene amplification. Ba/F3/T315I was transfected with a BCR‐ABL gene encoding T315I‐mutated BCR‐ABL. Ponatinib inhibited the growth of both K562/IM‐R1 and Ba/F3/T315I as potently as it inhibited their parental cells with an IC (50) of 2–30 nM. Panobinostat also similarly inhibited the growth of all of the cell lines with an IC (50) of 40–51 nM. This was accompanied by reduced histone deacetylase activity, induced histone H3 acetylation, and an increased protein level of heat shock protein 70, which suggested disruption of heat shock protein 90 chaperone function for BCR‐ABL and its degradation. Importantly, the combination of ponatinib with panobinostat showed synergistic growth inhibition and induced a higher level of apoptosis than the sum of the apoptosis induced by each agent alone in all of the cell lines. Ponatinib inhibited phosphorylation not only of BCR‐ABL but also of downstream signal transducer and activator of transcription 5, protein kinase B, and ERK1/2 in both K562/IM‐R1 and Ba/F3/T315I, and the addition of panobinostat to ponatinib further inhibited these phosphorylations. In conclusion, panobinostat enhanced the cytotoxicity of ponatinib towards IM‐resistant CML cells including those with T315I‐mutated BCR‐ABL.
format Online
Article
Text
id pubmed-4946706
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49467062016-07-27 Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells Matsuda, Yasufumi Yamauchi, Takahiro Hosono, Naoko Uzui, Kanako Negoro, Eiju Morinaga, Koji Nishi, Rie Yoshida, Akira Kimura, Shinya Maekawa, Taira Ueda, Takanori Cancer Sci Original Articles The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resistant CML cells in vitro. Two different IM‐resistant cell lines, K562/IM‐R1 and Ba/F3/T315I were evaluated in comparison with their respective, parental cell lines, K562 and Ba/F3. K562/IM‐R1 overexpressed BCR‐ABL due to gene amplification. Ba/F3/T315I was transfected with a BCR‐ABL gene encoding T315I‐mutated BCR‐ABL. Ponatinib inhibited the growth of both K562/IM‐R1 and Ba/F3/T315I as potently as it inhibited their parental cells with an IC (50) of 2–30 nM. Panobinostat also similarly inhibited the growth of all of the cell lines with an IC (50) of 40–51 nM. This was accompanied by reduced histone deacetylase activity, induced histone H3 acetylation, and an increased protein level of heat shock protein 70, which suggested disruption of heat shock protein 90 chaperone function for BCR‐ABL and its degradation. Importantly, the combination of ponatinib with panobinostat showed synergistic growth inhibition and induced a higher level of apoptosis than the sum of the apoptosis induced by each agent alone in all of the cell lines. Ponatinib inhibited phosphorylation not only of BCR‐ABL but also of downstream signal transducer and activator of transcription 5, protein kinase B, and ERK1/2 in both K562/IM‐R1 and Ba/F3/T315I, and the addition of panobinostat to ponatinib further inhibited these phosphorylations. In conclusion, panobinostat enhanced the cytotoxicity of ponatinib towards IM‐resistant CML cells including those with T315I‐mutated BCR‐ABL. John Wiley and Sons Inc. 2016-06-21 2016-07 /pmc/articles/PMC4946706/ /pubmed/27166836 http://dx.doi.org/10.1111/cas.12965 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Matsuda, Yasufumi
Yamauchi, Takahiro
Hosono, Naoko
Uzui, Kanako
Negoro, Eiju
Morinaga, Koji
Nishi, Rie
Yoshida, Akira
Kimura, Shinya
Maekawa, Taira
Ueda, Takanori
Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title_full Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title_fullStr Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title_full_unstemmed Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title_short Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
title_sort combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant cml cells
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://www.ncbi.nlm.nih.gov/pubmed/27166836
http://dx.doi.org/10.1111/cas.12965
work_keys_str_mv AT matsudayasufumi combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT yamauchitakahiro combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT hosononaoko combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT uzuikanako combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT negoroeiju combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT morinagakoji combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT nishirie combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT yoshidaakira combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT kimurashinya combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT maekawataira combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells
AT uedatakanori combinationofpanobinostatwithponatinibsynergisticallyovercomesimatinibresistantcmlcells